Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $56.368 million which beat the analyst consensus estimate of $16.273 million by 246.38 percent. This is a 99.03 percent increase over sales of $28.321 million the same period last year.